pirtobrutinib
1 product
11 abstracts
Abstract
Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma.Org: Medical College of Wisconsin Center for AIDS Intervention Research, Medical College of Wisconsin, Division of Hematology & Oncology,
Abstract
Real-world understanding of the unmet need for treatment of non-covalent BTKi in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ,
Abstract
Efficacy outcomes of treatments for double exposed chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic literature review.Org: Clinical and Administrative Pharmacy, Health Economics and Health Services Research,
Abstract
A phase IIA clinical trial to evaluate a reversible Bruton’s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).Org: Chengdu Hyperway Pharmaceuticals, Chengdu, China,
Abstract
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.Org: UCI Health, Medical College of Wisconsin, Maria Sklodowska-Curie National Research Institute of Oncology, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Linear Clinical Research and Sir Charles Gairdner Hospital,
Abstract
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Department of Hematology and Cancer Prevention, Medical University of Silesia, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Memorial Sloan Kettering Cancer Center,
Abstract
BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Ohio State University Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, Sir Charles Gairdner Hospital, Loxo Oncology at Lilly, Eli Lilly and Company,
Abstract
Treatment outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: A comparison between pediatric-inspired regimens and HyperCVAD at a Hispanic-serving cancer center.Org: University of California, Irvine, Irvine, CA, Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Product
LOXO-305